I. MODIFIED AGREEMENTS | |||
Biotech Co.* |
Pharma Co. |
Change from original agreement | Terms/Details (Date) |
| | |||
Actelion Ltd. |
UCB Pharma (Belgium) |
They replaced existing license deal covering the Gaucher's disease product Zavesca |
Actelion assumes full responsibility for the pre-UCB obligations on manufacturing and supply, and clinical development; UCB gets an up-front payment in return for a single- digit royalty rate on future sales (11/17) |
Cambridge |
Abbott Laboratories |
They reached an agreement regarding royalties payable to CAT under a licence agreement covering Humira |
CAT gets $255M, which it will pay to its licensors; it also gets five annual payments of up $9.375M; CAT's royalty payments were reduced to 2.688% of sales from 5.1% (10/26) |
Cephalon Inc. |
Ranbaxy Laboratories Ltd. (India) |
They settled patent infringement dispute in the U.S. related to Provigil (modafinil) |
Ranbaxy got a nonexclusive, royalty-bearing right to market a generic version of the product starting in 2011; they also entered a series of business arrangements related to modafinil (12/22) |
Cephalon Inc. |
Teva Pharmaceutical Industries Ltd. (Israel) |
They settled patent infringement disputes in the U.S. and UK related to Provigil (modafinil) |
Teva got a nonexclusive, royalty-bearing right to market a generic version of the product starting in 2011; they also entered a series of business arrangements related to modafinil (12/9) |
CuraGen |
Bayer Pharmaceuticals Corp. |
They revised terms of deal in metabolic disorders relating to development of BAY 76-7171 (formerly CT052) |
CuraGen exercised its right to revert to a tiered royalty structure on any sales and no longer will contribute to development costs of the drug (12/20) |
Depomed |
Biovail Corp. (Canada) |
They resolved a dispute regarding a license agreement on the metformin-based diabetes product Glumetza |
Under the new deal Depomed has rights to the product in the U.S.; Biovail relinquished its option to develop metformin combination products; Depomed withdrew legal action following the agreement (12/13) |
Enzon |
Sanofi-Aventis Group (France) |
They amended license agreement covering the leukemia drug Oncospar |
Enzon will pay a single-digit royalty rate on annual sales that exceed $25M; it had been paying 25% on all sales; Sanofi gets an up-front cash payment of $35M (10/31) |
Genetic |
Applera Corp. |
The companies settled a patent dispute initiated by Gene Technologies in 2003 |
Terms were not disclosed but do include a license to the non-coding patents from Genetic Technologies (12/12) |
Gilead |
F. Hoffmann-La Roche Ltd. (Switzerland) |
They resolved a dispute related to their 1996 deal covering the influenza drug Tamiflu |
Gilead gets $62.5M in adjusted royalties, and will get sales royalties from 14% to 22%; Gilead also gets certain co-promotion options in the U.S.; the deal ends arbitration proceedings (11/16) |
Savient |
Barr Pharmaceuticals Inc. and NV Organon (the Netherlands) |
They settled patent litigation regarding Barr's generic version of Mircette, an oral contraceptive product |
Barr paid Savient $13.75M, of which about $2.8M will be passed on to the inventor (12/2) |
II. TERMINATED AGREEMENTS | |||
Aphton Corp. |
Sanofi Pasteur (France) |
They ended a deal from 1997 to develop Aphton's immunotherapy compound Insegia |
Aphton regained rights to the G17DT immunogen, which is being developed for cancers, and intends to find a new partner (11/9) |
Avalon |
Sanofi-Aventis Group (France) |
They ended December 2003 collaboration using molecular cytogenetics to identify and validate oncology targets |
The agreement expired as a result of Sanofi's decision not to advance targets from the collaboration (12/21) |
Arqule Inc. |
Pfizer Inc. |
Pfizer is ending deal under which Arqule has been producing synthetic chemical compounds for Pfizer |
The deal, started in 2001, will end May 22, 2006; Arqule expects to receive $19.8M in connection with the termination notification (12/6) |
Discovery |
Pfizer Inc. |
The companies terminated discussions regarding a potential new deal to replace existing one about to expire |
Discovery has received about $92M from the chemistry deal from 2002 to 2005; Discovery will reduce its combinatorial chemistry operations as a result (11/29) |
| | |||
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
SWX = Swiss Stock Exchange. | |||
To read more on related topics, click on one of the words below.